INCREASING HUMAN PAPILLOMAVIRUS VACCINATION IN YOUNG ADULTS

By

Julie Renae Jennings, RN, CCRN,
BSN, University of Washburn, 2012

Submitted to the School of Nursing and
The Graduate Faculty of the University of Kansas
In partial fulfillment of the requirements for the degree of
Doctor of Practice.

Janet D. Pierce, Ph.D., APRN, CCRN, FAAN, Chair

Diane Mahoney, DNP, FNP-BC, EHNP-BC, Co-Chair

Date Project Proposal Accepted
The DNP Project committee for Julie R. Jennings certifies that this is the
approved version of the following DNP Project:

INCREASING HUMAN PAPILLOMAVIRUS VACCINATION IN
YOUNG ADULTS

Janet D. Pierce, Ph.D., APRN, CCRN, FAAN

Co-Chair:
Diane Mahoney, DNP, FNP-BC, EHNP-BC

Date Approved:
October 22, 2017
Increasing Human Papillomavirus Vaccination in Young Adults

Julie Jennings, RN, BSN, CCRN
Specialty Area: Family Nurse Practitioner

Committee Chair: Janet D. Pierce, Ph.D., APRN, CCRN, FAAN
Committee Co-Chair: Diane Mahoney, DNP, FNP-BC, EHNP-BC

Problem: The Human Papillomavirus (HPV) is a group of more than 150 viruses that are a causative agent in many types of cancers. This virus can be linked to cervical cancer, vulvar cancer, vaginal cancer, penile cancer, anal cancer, and throat cancer. There are currently three approved vaccines to prevent the spread of HPV that are known to be associated to these cancers. The number of young adults in the United States that receive HPV vaccine is low. One of the reasons identified for not receiving the HPV vaccine is a knowledge deficit related to the disease and the vaccine.

Project Aim: The aim of this quality improvement project will be to increase the number of HPV vaccines given to young adults (ages 18-26) through an educational pamphlet related to HPV and the HPV vaccines. The Project Director assumes that providing an educational pamphlet to young adults before they see their health care provider will increase the number of HPV vaccines administered at in a clinic setting (ComCare).

Project Method: This quality improvement project was conducted at ComCare in Salina, Kansas. An educational pamphlet about HPV and the HPV vaccine was constructed from the literature and input from four healthcare professionals, including three nurse practitioners and one physician. A five-question pre-survey concerning the HPV vaccine and patient demographics was provided to the 10 healthcare providers at ComCare. Providers were given one week to complete the surveys. The pamphlets were then made available to young adult patients at this clinic for a six-week period by being placed in the waiting room, as well as in patient care areas. After the six-weeks were completed, the providers were given a six-question post-survey to determine the effectiveness of the educational pamphlets.

Results: Nine out of the 10 providers at ComCare completed the pre-survey and eight out of 10 providers completed the post-survey. The post surveys showed a slight increase in the number of patients who had received the vaccine as well as the number of patients who initiated the vaccine each week. At ComCare, 89% of providers indicated that an educational deficit was why patients refused the HPV vaccine. There were 62% of providers at ComCare thought that the pamphlets were beneficial in their care, related to HPV, for young men and women age 18 to 26 in their clinic.

Conclusion: Pamphlets containing educational information on HPV and HPV vaccines in a clinic setting appears to be useful in increasing the number of HPV vaccines administered. Providers in the clinic setting identified the largest factor related to not vaccinating against HPV was an educational deficit. Further studies should be conducted in additional clinics to determine
if educational pamphlets are beneficial in increasing the number of young adults that obtain the HPV vaccine.
# Table of Contents

Introduction ..................................................................................................................................... 5  
Literature Review............................................................................................................................ 6  
Pathophysiology of HPV ............................................................................................................. 7  
  Host Defense............................................................................................................................ 7  
  HPV Invasion .......................................................................................................................... 8  
Vaccines ...................................................................................................................................... 8  
  Efficacy.................................................................................................................................... 8  
  Safety ....................................................................................................................................... 9  
  Prevalence................................................................................................................................ 9  
Reason for Not Vaccinating ...................................................................................................... 10  
  Education............................................................................................................................... 10  
  Not at Risk/Sexually Active .................................................................................................. 11  
  Side Effects/Safety ................................................................................................................ 12  
  Cost........................................................................................................................................ 13  
  Provider Recommendations................................................................................................. 14  
  Education Interventions......................................................................................................... 14  
Summary ................................................................................................................................... 15  
Project Aims.................................................................................................................................. 16  
  Theoretical Framework ............................................................................................................. 16  
Definitions..................................................................................................................................... 17  
  Conceptual Definition: Educational Information ................................................................. 17  
  Operational Definition: Education Information ................................................................. 17  
  Conceptual Definition: Young Adult .................................................................................... 18  
  Operational Definition: Young Adult .................................................................................... 18  
  Conceptual Definition: Initial dosage ................................................................................... 18  
  Operational Definition: Initial dosage ................................................................................... 18  
Methods......................................................................................................................................... 18  
  Design...................................................................................................................................... 18  
  Project Sample and Selection............................................................................................... 19  
  Data Collection....................................................................................................................... 19  
Results........................................................................................................................................ 20  
Discussion................................................................................................................................... 22  
  Limitations ............................................................................................................................. 24  
Conclusion .................................................................................................................................... 25
Introduction

Human papillomavirus (HPV) is a group of more than 150 related viruses that are transmitted through direct skin-to-skin contact, usually sexual, with an infected person (Center for Disease Control and Prevention [CDC], 2015). The virus is most commonly spread through vaginal or anal sex, but can be transmitted following nonpenetrative sexual activity. Currently, one in four Americans are infected with HPV (CDC, 2015). The most at risk group for HPV are sexually active women, under the age of 25, but many sexually active men and women get HPV at some point in their lives (Palefsky, 2016).

HPV is the causative agent in cell changes that result in genital warts and several cancers. Over 27,000 women and men are affected by a cancer caused by HPV annually. This virus can be linked to almost all cervical cancers, 91% of anal cancers, 75% of vaginal cancers, 72% of throat cancers, 69% of vulvar cancers, and 63% of penile cancers (CDC, 2015). Many of these cancers do not have signs or symptoms until they are in the advanced stages making treatment difficult. Statistics from the CDC (2015) show that from 2005-2009 there were 3,968 deaths annually due to cervical cancer, which were nearly all related to HPV. Currently, HPV can be identified at the causative agent in half a million deaths worldwide every year (Westrich, Warren, Pyeon, 2016).

Statement of the Problem

HPV is a group of viruses that currently has one of the highest incidence rates when compared with other STIs in the United States. It is estimated that there are nearly 20 million new sexually transmitted diseases (STIs) in the United States annually. HPV attains for nearly 50% of these newly acquired STIs. Although about 90% of new HPV infections will
spontaneously resolve within two years, the care for the remaining 10% is rather costly due to the expense of treating HPV related cancers (World Health Organization, 2016).

The medical costs to care for individuals who acquire a new STI totals around $16 billion. Annual costs for preventing and treating HPV associated diseases was estimated to be $8.0 billion in 2010 (Chesson, Ekwueme, Saraiya, Watson, Lowy, & Markowitz, 2012). There is currently no cure for the HPV virus thus; one method to address this issue is through prevention of the virus.

There are currently three different multi-dose vaccine series available that provide immunity against HPV strands that are known to cause multiple cancers and genital wart (Smulian, Mitchell, & Stokley, 2016). Unfortunately, the CDC (2015) found that HPV vaccination initiation and completion rates are lower than desired by healthcare professionals. This leaves many people at risk for a multitude of cancers and genital warts. Low rates of immunizations, also increase the financial burden related to this disease.

The World Health Organization (WHO) (2016) recommends a comprehensive approach to preventing and controlling HPV related illnesses. This includes community education, social mobilization, vaccination, screening, treatment, and palliative care. It is important for healthcare providers to educate patients and develop ways to decrease the number of newly acquired HPV infections. Primary prevention interventions, such as vaccinations, are recommended prior to exposure and acquisition of HPV. It can also decrease the financial constraints observed throughout the American healthcare system due to HPV incidences and related illnesses.

**Literature Review**

A literature review was conducted from August 2016 to March 2017 to determine common causes of not receiving the vaccination and interventions that help increase the
initiation of the HPV vaccine series. The databases that were search included PubMed and CINAHL. The keywords searched included human papillomavirus, HPV, vaccine, interventions, and increase uptake. The search was limited to English articles that were published between 2011 and 2016. The articles title and abstracts were reviewed to determine relevance to the study for inclusion into the literature review section.

Data from the articles that were relevant were placed on the matrix in Appendix A. The matrix contains the citation, level of evidence, sample/setting, data collection/interventions, key findings, limitations, and summary of findings. The matrix includes 16 articles total.

**Pathophysiology of HPV**

HPV is a small double-stranded deoxyribonucleic acid (DNA) virus that infects the basal epithelial cells of the skin and mucosal membranes and can cause different types of warts and benign or malignant tumors (Sabeena, Bhat, Kamath, & Arunkumar, 2017; Westrich, Warren, & Pyeon, 2016). The transmission of the virus is species specific and most commonly transmitted through sexual contact (Sabeena, et al., 2017). For HPV to initiate infection, it must translocate across skin and mucous membranes. After the virus invades the host, it must withstand multiple defense mechanisms of the body. To do this, HPV interferes with multiple cellular pathways to evade the host immune response.

**Host Defense**

Mucous membranes pose a major physical barrier to the virus due to the secretion of viscous protective fluid and antimicrobial peptides (Sabeena, et al., 2017). Once the virus has invaded a host cell, innate pathogen sensors recognize the pathogen. When the pathogen has been detected, innate immune cells, such as dendritic, Langerhans, natural killer, and natural killer T cells, move to the HPV-infected environment (Westrich, Warren, & Pyeon, 2016). The
secretion of various cytokines, interferon-α (IFN-α), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), and IL-8, occurs when the innate immune cells are activated. The host T cell responses are required for elimination of HPV, but antibody titers from natural immunity are usually too low to protect the host against the virus (Westrich, Warren, & Pyeon 2016).

**HPV Invasion**

After the virus invades the host cell, the virus enters the nucleus. The virus then alters the host DNA methylation process, which is responsible for distinct gene expression patterns. The virus then manipulates host transcription (Mallen-St Clair, Alani, Wang, & Srivatsan, 2016).

The host immune response is altered due to expression of HPV oncoproteins E6 and E7, which quickly inactivate several tumor suppressors and causes chemotaxis of various immune cells. E6 and E7 oncoproteins also interact with multiple host proteins and change their activity to enhance virus replication and persistence. This inadvertently induces cellular malignancy (Mallen-St Clair, et al., 2016).

**Vaccines**

There are currently three vaccines approved in the United States to prevent HPV and related illnesses (CDC, 2015). All three of the vaccines cover HPV strands 16 and 18, which are the agents known to cause cancers. HPV strands six and 11 are covered by two vaccines and these strands are the causative agent of HPV related genital warts. One of the vaccines that covers strands six and 11 also covers strands 31, 33, 45, 52, and 58, which have been found to cause cervical, vulvar, and vaginal diseases (WHO, 2016).

**Efficacy**

The bivalent HPV vaccine (bHPVV) is effective against HPV strands 16 and 18, and is available for females aged ten to 25 (CDC, 2015). In females aged 15-25, the efficacy of the
vaccine in preventing cervical intraepithelial neoplasm (CIN2) is 94.9% and in preventing CIN3 is 91.7%.

The quadrivalent HPV vaccine (qHPVV) is effective against HPV strands 6, 11, 16, and 18. It is available to females and males aged nine through 26 (CDC, 2015). In females aged 16-26 year, qHPVV has an efficacy rate of 98.2% in preventing CIN2/3, 100% in preventing vulvar intraepithelial neoplasm (VIN) 2/3, and 99% in preventing genital warts. In males 16 to 26, qHPVV has an efficacy of 77.5% in preventing anal intraepithelial neoplasm (AIN).

The third vaccine is the newest and is a nine valent HPV vaccine (9HPVV). 9HPVV protects against HPV strands six, 11, 16, 18, 31, 33, 45, 52, and 58. Studies related to the 9HPVV are limited because it is relatively new. 9HPVV has shown to be non-inferior to qHPVV in preventing CIN and VIN in females ages 16 to 26, but was effective in preventing persistent infection and conditions related to HPV strands 31, 33, 45, 52, and 58 (Audisio, et al., 2016).

**Safety**

Local reactions, such as pain, redness, and swelling, are the most common side effects of both bHPVV and qHPVV. According to Audisio, et al. (2016), no serious adverse events have been found with either bHPVV or qHPVV. They found that pyrexia, headache, myalgia, and arthralgia have been reported. The WHO (2016) has reviewed reports on bHPVV and qHPVV and has determined that both vaccines have excellent safety and efficacy profiles.

**Prevalence**

In 2012, 28.1% of females aged 13 to 15 years had received all recommended doses of HPV vaccine (Healthy People 2020, 2016). According to the CDC (2015), the current rates for the HPV vaccine initiation in children 12 – 17 in the state of Kansas are less than 59% in girls and less than 39% in boys. The overall goal of Healthy People 2020 (2016) is to promote healthy
sexual behaviors, strengthen community capacity, and increase access to quality services to prevent sexually transmitted infections (STIs) and their complications. To reach this goal, Healthy People 2020 (2016) recommends that completion rate of the three dose HPV vaccine series is 80% in adolescent females aged 13 to 15 (Healthy People, 2016).

**Reason for Not Vaccinating**

Of the articles reviewed, 10 discussed the reasons why individuals were not receiving the HPV vaccine. Common themes found in this group include not enough education, side effect/safety, cost, no physician recommendation, and thoughts of being not at risk/or sexually active.

**Education**

Knowledge about HPV and the HPV vaccines is a modifiable risk factor that significantly contributes to under-vaccination. Nine articles reviewed found that one of the major reasons that vaccination rates are so low is due to a need for more education. Ratanasiripong (2012) and Small, Sampselle, Martyn, and Dempsey (2013) conducted systematic reviews that both found conflicting evidence related to the influence an educational deficit has on vaccinating. Ratanasiripong (2012) determined there is a direct relationship between knowledge and the intent to vaccinate. The lack of knowledge related to HPV and the HPV vaccine can result in misconception and negative attitudes toward the vaccine.

Researchers have examined why women 18 to 26 years of age are not vaccinating against HPV. Wilson, et al. (2016) found that 28% of the participants (n=325) who were not vaccinated wanted more information about the vaccine. The need for more education was the most common reason for not vaccinating in this study. Laz, Rahman, and Berenson (2013) found that 12.7% of the participants (n=1892) needed more information about the vaccine, which was the second
most common reason to decline vaccination. Schmidt and Parsons (2014) found that in 2008 17% of participants (n=782) indicated they did not know enough about the vaccine, which dropped to 12% in 2012 (n=988).

Taylor et al. (2014) and Wong et al. (2011) surveyed mothers who had a daughter in the 9-17 age range. Taylor et al. (2014) found that 43% of mothers (n=49) identified a lack of knowledge as their reason for not vaccinating their daughters against HPV. In a larger study by Wong, et al. (2011), 17.7% of participants (n=1105) identified a lack of knowledge as a reason for not vaccinating, which was the second most common reason to decline vaccination.

Oldach and Matz (2012) and Head, Vanderpool, and Mills (2013) used healthcare professional’s opinions to determine common reasons for refusal of the HPV vaccine. Oldach and Matz (2012) found that 55.6% of healthcare professionals (n=50) identified a lack of knowledge as a barrier to the vaccine, which was the most common reason in the study. In a smaller qualitative study of 15 healthcare professionals, one of two common themes for low HPV vaccine uptake was because patients did not think they needed the vaccine (Head, Vanderpool, & Mills, 2013). It was identified from the interviews that patients do not understand the link between HPV and cervical cancer, therefore identifying a knowledge deficit amongst these patients.

Not at Risk/Sexually Active

Nine articles were identified that indicated patient’s perception of not being at risk or not being sexually active as a reason for not vaccinating against HPV. Small, Martyn, and Dempsey (2013) performed a systematic review of literature and found that patient’s perception of risk was a significant contribution to not vaccinating, but did not indicate that sexual inactivity was a
factor. In a systematic review of literature, Ratanasiripong (2012) reported sexual inactivity as a significant reason for not vaccinating in women aged 18 – 26.

Young women aged 18-26 was the target population for multiple studies. An observational study (n=325) found that 10% of the study sample indicated not needing the vaccine due to sexual inactivity (Wilson, et al., 2016). Patel, et al., (2012) (n=80) found that not being at risk (28.8%) was the least common reasons found for not vaccinating against HPV. Schmidt and Parsons (2014) found both the perception of not being at risk and sexual inactivity as reasons for not vaccinating in their analysis of surveys from 2008 and 2010. In 2008, 35.9% of participants (n=782) indicated they did not need the vaccine, while only 10.3% of participants reported sexual inactivity as their reason for not vaccinating against HPV. In this study, 40.7% of participants (n=988) indicated not needing the vaccine and 8.1% of the participant’s reported sexual inactivity as their reason for not getting vaccinated against HPV in 2010. Another survey conducted in 2010 found that 39.6% of women aged 18-26 (n=1478) do not receive vaccinations against HPV because they do not think they need the vaccine (Laz, Rahman, & Berenson, 2013).

Parents of young girls aged nine to 17 indicated that their daughters did not need the vaccine or were sexually inactive in two studies. Taylor, et al. (2014) found 26% of parents (n=49) indicated this (n=49) as their reason for not vaccinating. A larger study found that 35.2% of parents (n=1105) indicated that their daughter does not need the vaccine or is not sexually active (Wong, et al., 2011).

**Side Effects/Safety**

Side effects and/or safety were reasons for not vaccinating in six articles reviewed. In a systematic review of literature by Small, et al. (2014), safety concerns influenced vaccine uptake in 24% of participants in three studies with a variety of populations including parents and young
women aged 18-26. Ratanasiripong (2012) found a wide range of < 5% - 42.9% of participants indicated safety concerns as a reason for not vaccinating in a systematic review.

A survey conducted in 2008 and 2010 found that 12.6% of women age 26 years old were worried about the safety of the HPV vaccines (n=782) and 12.3% respectively (Schmidt & Parsons, 2014). Wilson, et al. (2016) found 13% of the 26 year old women (n=136) were concerned with safety and side effects. In a study of 26 year old female college students (n=80), 48.8% of participants indicated concerns about safety and side effects as reasons they were not getting vaccinated against HPV (Patel, et al. 2012). Another study found 37.8% of health care professionals (n=50) indicated that among parents of male and female adolescents their concerns about safety were barriers to HPV vaccination (Oldach & Katz, 2012).

Cost

The cost of the HPV vaccine can vary significantly due to variations in insurance coverage. Small, et al. (2014) found that cost and insurance coverage influenced young adult’s decision to vaccinate, but is less of a concern for the younger population. They indicated this difference is most likely because children 19 and younger are usually insured and may be eligible for free vaccines through the Vaccine for Children (VFC) program.

In a study of women 18-26 years of age (n=1892), cost was an issue for 2.6% of participants (Las, Rahman, & Berenson, 2012). This concern was highest in participants that did not have insurance (n=276; 5.3%). A survey of U.S. women age 18-26-years of age found that in 2008 (n=782) and in 2010 (n=988) 1.8% and 2.5% participants indicated the HPV vaccine was too expensive (Schmidt & Parsons, 2014). In an observational study of college women (n=136), Wilson, et al. (2016) found that cost of the HPV vaccine was a main reason for not receiving the vaccine in 17% of participants (n=325). Patel, et al. (2012), who also studied college women,
found that cost of the vaccine was a significant concern to 41.3% of participants (n=80). A study of barriers reported by providers (n=45) found that 8.9% of providers find cost to be an issue in participants that do not qualify for the VFC program (Head, Vanderpool, & Mills, 2013). Cost was not a significant concern for parents of young girls between the ages of nine and 17 (n=1105, 1.6%) (Wong, et al., 2011).

**Provider Recommendations**

If a provider does not recommend the HPV vaccine to patients, the uptake of the HPV vaccine can be affected. According to Small, et al. (2014), who performed a systematic review of literature, indicated that provider recommendation is one of the most clinically significant factors that has shown an increase in HPV vaccine uptake. A survey in 2008 (n=782) and 2010 (n=988) of U.S. women aged 18-26 found that no provider recommendation was the reason 5.4% and 7.4% women did not receive the HPV vaccine. Another survey on women aged 18-26 found that 7.2% of participants (n=1892) did not get the HPV vaccine because their healthcare provider did not recommend it (Las, Rahman, & Berenson, 2012).

Taylor, et al. (2014) surveyed parents of girls aged nine to 17 (n=49) and found that 24% of participants reported no physician recommendation as their reason for not vaccinating their child. Another study of parents of young girls found that not receiving physician recommendation was less common of a reason to refuse the HPV vaccine. This study found that 5.5% of parents refused the HPV vaccine due to not receiving physician recommendation for it (Wong, et al, 2011).

**Education Interventions**

A limited number of studies used educational interventions as a variable to increase the initiation of the HPV vaccine series. A systematic review of literature conducted by Fu,
Bonhomme, Cooper, Joseph, and Zimet (2014) found educational trials directed toward parents, adolescence, and young adults did not show a significant increase in HPV vaccine uptake after intervention. Although these trials did not show significance, Fu, et al. (2014) concluded from their review that the intent of adolescents and young adults to receive the HPV vaccination could be influenced by education interventions. They also found that participants who received their initial HPV vaccine at the time of an educational intervention were more likely to complete the 3-dose series.

Another systematic review found differing results related to the impact of educational interventions. They concluded that patient education showed a modest increase in the initiation of the HPV vaccine. They also found that interventions that were both provider and community based had the greatest impact on vaccine uptake (Smulian, Mitchell, & Stokley, 2016).

**Summary**

Although there is not strong evidence indicating educational interventions will greatly affect the initiation of the HPV vaccine series, education related to HPV vaccine is needed. Of the reasons indicated for not receiving the HPV vaccine, not enough education, side effects/safety, and perception of not being at risk or sexually active are possible reasons where educating patients about HPV and the HPV vaccine could change their decision concerning vaccinations.

With the consistent rise in individuals infected with HPV, it is important that interventions to increase vaccination rates be pursued. As vaccination rates increase, the risk of acquiring an HPV related cancers or illnesses would begin to decrease. The goal of Health People 2020 is an 80% vaccination rate, which will require interventions to increase compliance with the CDC recommendations related to the HPV vaccine.
**Project Aims**

Current literature suggests that there is a knowledge deficit pertaining to HPV and the HPV vaccine. Although there is no specific intervention that has shown an increase in the uptake of the HPV vaccine, there are studies that show educational interventions do increase the intent to vaccine and improve overall knowledge about HPV and the HPV vaccine.

The **aim** of this quality improvement (QI) project is to increase the number of HPV vaccines given to young adults (ages 18-26 years old) through an educational pamphlet related to HPV and the HPV vaccines. The project question developed is: Will the use of an education pamphlet on HPV and the HPV vaccines increase the initial uptake of the HPV vaccine in young adults aged 18-26? The Project Director assumes that providing an educational pamphlet to young adults before they see their health care provider will increase the number of HPV vaccines administered at ComCare in Salina, Kansas.

**Theoretical Framework**

The Plan-Do-Study-Act (PDSA) framework was chosen for this QI project. The purpose of the PDSA framework is to establish a functional relationship between process changes in systems of healthcare and variations in outcomes (Speroff & O’Connor, 2004). By following this framework, the question “How will we know that a change is an improvement?” will be answered (Speroff & O’Connor, 2004).

The PDSA model is a four-stage cyclic learning approach. The model mirrors the scientific method and is used to adapt changes aimed at improvement. This framework follows four major steps. Taylor, et. al (2013) describe the steps as: “In the ‘plan’ stage a change aimed at improvement is identified, the ‘do’ stage sees this change tested, the ‘study’ stage examines
the success of the change and the ‘act’ stage identifies adaptations and next steps to inform a new cycle” (Taylor, McNicholas, Nicolay, Darzi, Bell, & Reed, 2013) (p. 291).

Following the PDSA framework, a plan was developed for this QI project. The change that this project evaluated is the use of educational pamphlets about HPV and the HPV vaccine at ComCare in Salina, Kansas. The goal of the project was to increase the HPV vaccine in young adults aged 18-26 by educating them on HPV and the HPV vaccine. To determine if the use of educational pamphlets made an improvement in vaccine uptake, providers within the clinic completed pre- and post-intervention surveys. After data were collected, the Project Director reviewed the surveys and interrupt the data to determine if the use of educational pamphlets increased the uptake of the HPV vaccine. The findings were shared with the healthcare providers at ComCare.

Definitions

**Conceptual Definition: Educational Information**

An educational pamphlet is a document that provides the reader with general information about a specific subject. Educational information should be designed to improve patient knowledge or attitude (Fu, et al., 2014). Educational information is defined by Patel, el al. (2013), as a fact sheet that is molded from information from the CDC.

**Operational Definition: Education Information**

For this QI project, the education information will be provided in the form of an educational pamphlet. The pamphlets are a single sheet of paper, both front and back, in an easy to read format. Information about HPV and the HPV vaccine was obtained from the CDC and the Immunization Action Coalition. There was also input from four different content experts, consisting of one Physician and three Nurse Practitioners.
**Conceptual Definition: Young Adult**

Young adults can be defined as individuals, both male and female, between the ages 20 – 26 (Fu, et al., 2014). This age group of individuals are usually at a higher risk for STIs due to a combination of behavior, biological, and cultural reasons.

**Operational Definition: Young Adult**

For this QI project, a young adult is defined as any male or female between the ages of 18 and 26. There will be no regulations related to ethnicity. This age group was chosen because at the age of 18 individuals can make informed consent. The HPV vaccine can be administered to individuals up until the age of 26 years old, so this allow all individuals who are able to make informed consent and receive the vaccine be included in the study.

**Conceptual Definition: Initial dosage**

Patel, et al. (2012) defined the initial dosage as receiving the first dose of the vaccine series. The participant cannot have received a dose of the HPV vaccine within their lifetime.

**Operational Definition: Initial dosage**

The initial dosage for this QI project will be defined as receiving at least one dose of the HPV vaccine series. For this QI project, there will be no requirements related to time of initial dose or uptake of subsequent doses.

**Methods**

**Design**

This project is an evidence based QI project. The Institutional Review Board at the University of Kansas Medical Center reviewed the protocol and gave permission to perform this QI project (Appendix D). Management at ComCare in Salina, Kansas was contacted about this QI project and provided the Project Director a letter of approval (Appendix G) to perform this QI
project. Prior to distribution of the pre-survey, providers at ComCare were sent a letter (Appendix E) informing them about this QI project and asking them for their participation in this QI project.

Providers at ComCare in Salina, Kansas were given a pre-survey (Appendix B), to determine how many HPV vaccines they recommend, how many HPV vaccines are provided, reasons for patient refusal of the HPV vaccine, and patient demographics. After the pre-survey was completed, educational pamphlets (Appendix F) were distributed. These educational pamphlets include information about HPV and the HPV vaccine from evidence based and accredited websites, such as the CDC, as well as input from four different content experts. These experts consist of a one Physician and three Nurse Practitioners. The pamphlets were placed in the waiting room and examination rooms of the clinic. Once a week the Project Director ensured there were adequate amounts of pamphlets available to patients and answered any questions providers had.

After a six–week period, providers were asked to complete the post-survey (Appendix C) to determine if there were changes in the number of HPV vaccines recommended, number of HPV vaccines provided and/or the reasons for not vaccinating. Providers were also asked if they felt the educational pamphlets were beneficial to their practice.

**Project Sample and Selection**

The sample consisted of ten healthcare providers working at ComCare. The healthcare providers consisted of eight Physicians and two Nurse Practitioners who practice at the clinic.

**Data Collection**

Data were collected through pre- and post-surveys completed by the healthcare providers at ComCare. The information collected includes estimated number of HPV vaccines
recommended each week, estimated number of HPV vaccines given each week, reasons patients refuse the vaccine, age range of patients receiving the vaccine, sex of patients receiving the vaccine, and ethnicity of patients receiving the vaccine. The surveys the providers at ComCare completed include no identifying data to maintain confidentiality of the patients and providers.

**Results**

Nine out of 10 providers chose to participate in the pre-survey and eight out of 10 providers participated in the post-surveys. Frequency of answers to the survey questions are displayed in tables, bar charts, and pie charts. Demographic data were analyzed and all of the providers reported on both the pre- and post-surveys that the most common patients they met in the study population were white females between the ages of 18 and 22.

The first question of the surveys asked the providers on average, how many patients do you see in the clinic each week that are between the ages 18 and 26? *Figure 1* (Appendix H) shows the number of providers that responded for each option. The pre-survey showed that six providers (66%) reported that they met nine or more patients between the ages of 18 and 26 each week. On the post-survey showed five providers (63%) met nine or more patients between the ages of 18 and 26 each week. There was one provider in the clinic that met zero to two patients. One provider met three to five patients and one provider that met six to eight patients between the ages of 18 and 26 each week in both the pre- and post-surveys.

On the pre-survey, eight of the providers (89%) reported that zero to two of the patients they met each week had already initiated the HPV vaccine (*Figure 2*, Appendix H). Only one provider (11%) reported more than this, and they reported examining three to five of the patients each week that had already initiated the HPV vaccine. All nine providers, 100% of providers,
reported on the pre-survey that they have zero to two patients which initiated the vaccine each week (*Figure 3, Appendix H*).

*Figure 2* also shows the post survey results for the number of providers that had patients who had already initiated the HPV vaccine. Three of the providers (37.5%) reported they had three to five patients a week that had initiated the HPV vaccine series, while five (62.5%) providers, reported zero to two patients had initiated the HPV vaccine series. During the post survey, providers had more patients initiate the HPV vaccine series than in the pre-survey (*Figure 3, Appendix H*). Two providers (25%) reported that six to eight of their patients initiated the vaccine series a week, while six providers (75%) reported zero to two patients initiated the HPV vaccine each week.

Providers were asked to report reasons their patient refused the HPV vaccine. The most common reasons patients refuse the vaccine, from the literature review, include education deficit, cost, side effects/safety, and fear of shots. Providers were to choose all of the reasons that apply to their practice and *Figure 4* (Appendix H) illustrates these results. The most common reason for refusal of the HPV vaccine was an educational deficit. At ComCare, 89% of providers indicated this as a reason their patients refused the HPV vaccine. Another common reason for refusal was concerns about side effects or safety, where 56% of providers indicated this as a reason for vaccine refusal. There were 33% of providers indicating the cost of the vaccine was a concern for patients and 22% of providers indicated that their patients had a fear of shots.

During the post survey, providers were asked if they felt the educational pamphlet that had been placed throughout the ComCare clinic was beneficial in their care for young men and women aged 18 to 26. The results of this question showed that 62% of providers thought the
pamphlet was beneficial, 29% of providers thought that the pamphlet was not beneficial, and 14% of providers were not sure if they were beneficial (Figure 5, Appendix H).

Discussion

Overall, the response rate of the providers was excellent. There was a small sample size of 10 providers, but 90% of them responded to the pre-survey and 80% responded to the post-surveys. Between 63% and 66% of providers examined nine or more patients each week that met criteria for this QI project, which included that the patient being a male or female between the ages of 18 and 26.

The provider responses to reasons why patients were refusing the HPV vaccine in this QI project were similar to those found in literature. Oldach and Matz (2012) interviewed healthcare professionals and found the most common reason for vaccine refusal was due to an educational deficit. They found 55.6% of healthcare professionals identified educational deficit as the main reason for not vaccinating. A systematic review of literature by Ratanasiripong (2012) also found that the main reasons patients were refusing the HPV vaccine series was due to an educational deficit. The results of this QI project showed that educational deficit was the most common reason for HPV vaccine refusal as indicated by the healthcare providers participating in the survey. This QI project showed that 89% of providers identified an education deficit in their patients as the reason for vaccine refusal.

Patel, et al. (2012) found that 48.9% of women age 18 – 26 years of age were concerned of side effects and safety, which is comparable to the result of 56% reported by providers in this QI project. In this QI project, cost was the second most common reasons providers identified for patients not vaccinating against HPV. Oldach and Katz (2012) also determined safety and side effects were the second most common reason for not vaccinating against HPV in their study of
providers. They concluded that 37.8% of providers identified safety and side effects as a concern. While safety and side effects are concerns in multiple studies, it has been identified that all of the HPV vaccines have a low risk safety profile and high efficacy rates in preventing a variety of cancers.

Cost of the vaccines were identified as the third most common reason for not vaccinating in this QI project. It was determined that 33% of providers in this QI project identified cost as a barrier to patients receiving the HPV vaccine. Small, et al. (2012) found, in a systematic review of literature, cost influenced patient’s intent to vaccinate. They found this to be a bigger concern for young adults than adolescence. Patel et al. (2012) identified cost as a barrier and indicated that 41.3% of college women who participated in their study reported cost as a reason for not vaccinating. Wilson, et al. (2016), who also studied college aged women, found that 17% of participants identified cost as a concern related to receiving the HPV vaccine. Head, Vanderpool, and Mills (2013) found that 8.9% of providers identified cost as a barrier to patients receiving the HPV vaccine. When looking at studies of similar age groups, the results of this QI project are comparable to current literature.

The results of this QI project showed a slight increase in the number of patients that had started the HPV vaccine series and the number of HPV vaccines given each week. These results correlate to those concluded by Smulian, Mitchell, and Stokley (2016), who determined there was a modest increase in the initiation of the HPV vaccine with patient education. The results of this QI project differ from those found by Fu, et al. (2014), who found that educational trails for parents, adolescents, and young adults did not show significant increase in HPV vaccine uptake. However, these researchers did identify the intent to vaccinate increased in young adults when they were educated about HPV and the HPV vaccine.
The results of this QI project showed a slight increase in the number of patients that had started the HPV vaccine series and the number of HPV vaccines given each week. These results correlate to those concluded by Smulian, Mitchell, and Stokley (2016), who determined there was a modest increase in the initiation of the HPV vaccine with patient education. The results of this QI project differ from those found by Fu, et al. (2014), who found that educational trails for parents, adolescents, and young adults did not show significant increase in HPV vaccine uptake. However, these researchers did identify the intent to vaccinate increased in young adults when they were educated about HPV and the HPV vaccine.

Limitations

This QI project, using educational pamphlets to increase the uptake of the HPV vaccine, was performed over a six-week period. The results did show a slight increase in the number of patients who received the HPV vaccine, but it is unknown if the educational pamphlets were the specifically related to this increase. Conducting a longer study would be beneficial to help determine if the educational pamphlets assisted with the significant increase in HPV vaccinations. The sample of young adults that was sampled in this QI project was mainly white females between the ages of 18 and 22, which does not fully represent the population available to receive this vaccine. It would be beneficial to perform similar projects in a more diverse population.

The surveys used in this QI projects used ranges for the number of patients each provider cared for, the number of patients who had previously initiated the HPV vaccine, and the number of patients who initiated the HPV vaccine each week. The results of these questions could be more precise if whole numbers were used instead of ranges. In addition, providers estimated the
number of patients they cared for related to each of these questions. The results would be more precise if data were collected through chart review instead of provider recall and estimations.

While this QI project was intended to educate young adults aged 18 to 26, interventions should also look at ways to educate parents and adolescence. Patients should be receiving the HPV vaccine prior to exposure to HPV, which would be prior to sexual activity. Today the age of first sexual activity is becoming younger. Irala, Osorio, Ruiz-Canela, and Lopez-del Gurgo (2011) found that in the United States the mean age for first sexual intercourse is age 15. Thus, intervention for young adults may come too late to prevent HPV and HPV related diseases for all that vaccinate during this age.

**Conclusion**

The educational pamphlets showed to be beneficial in this clinic setting. The results of this QI project showed that there was a slight increase in the number of patients who received the HPV vaccine after the educational pamphlets were made available. This QI project identified that, according to providers, there is a significant educational deficit in patients related to HPV and the HPV vaccine. Providers in this clinic setting concluded that educational pamphlets were beneficial to their care related to HPV in young adults aged 18 to 26.

**Recommendations for Practice**

As the incidence rates of HPV infections and related cancers continues to rise, it is important that providers can identify ways to decrease rates. Patient education has been identified as a major deficit related to HPV. The HPV vaccine is just one topic that providers need to educate patients on related HPV prevention. Other topic that should be discussed with patients include abstinence, limiting sexual partners, and the use of condoms. Studies should
continue to be developed to assess if other educational interventions would be more beneficial than an educational pamphlet.

Research should continue to determine age-specific intervention that will help educate parents, adolescents, and young adults. Technology has become a part of everyday life and should be used as a tool to educate patients. Further research should be done to determine if educational interactive digital programs on tablets in the waiting room or educational clips delivered on tablets or televisions in waiting rooms would increase patient’s knowledge about HPV and the HPV vaccine.

The overall rates of HPV vaccination are low; therefore, interventions that are not age specific should be researched as well. Other methods to increase the uptake of the HPV vaccine that should be investigated to include an incentive gift for receiving the vaccine or a free vaccination day. While it was not the top reason for not vaccinating, the cost of the vaccine was identified as a reason for not vaccinating.
References


http://www.who.int/mediacentre/factsheets/fs380/en/
**Appendix A**

**Literature Review Matrix**

<table>
<thead>
<tr>
<th>Citation (author/year)</th>
<th>Level of Evidence</th>
<th>Design</th>
<th>Sample/Setting</th>
<th>Data Collection/Interventions</th>
<th>Key Findings</th>
<th>Limitations</th>
<th>Summary of Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fu, L. Y./2014</td>
<td>I</td>
<td>Systematic review</td>
<td>33 studies: 7 tested parental interventions; 8 studies tested the effectiveness of interventions with adolescents or young adults; 18 compared different message frames</td>
<td>PubMed and Web of Science databases searched -two authors independently reviewed articles to determine relevance</td>
<td>-education intervention trails showed no significant increase in uptake as a result of their interventions</td>
<td>- search restricted to English studies - bias for different methods for restig educational interventions</td>
<td>- adolescents and young adult’s intention to receive HPV vaccination may be more readily influenced by educational interventions - Enhanced single-session education may increase compliance with completion of the 3-dose series among participants who are given first dose at the time of the education</td>
</tr>
<tr>
<td>Head, K. J./2013</td>
<td>IV</td>
<td>Interview</td>
<td>- sample size 15: 6LPNs, 3NPs, 6Physicians - 1-hour interview - interview questions specifically focused on healthcare providers’ perceptions of barriers and facilitators to HPV vaccination uptake and adherence</td>
<td>- interview was audio recorded</td>
<td>- Reasons for low HPV vaccine uptake: (1) patient barriers – do not want a shot and do not think the vaccine is important (2) inadequate region- and age-specific HPV vaccination education and promotion - Reasons for low HPV vaccination adherence: (1) complications of three-dose vaccine schedule, (2) clinic-centered communication deficiencies</td>
<td>- limited generalizability – small sample and rural area - research team shares an affiliation with facility used - providers perspective of why vaccine is refused – risk for biased interpretations and inaccurate observations</td>
<td>- Reasons for low vaccine uptake: patient barriers and inadequate education and promotion</td>
</tr>
<tr>
<td>Laz, T. H./2012</td>
<td>IV</td>
<td>Survey with a cross sectional design; complex, stratified, multistage probability design.</td>
<td>1892 women aged 18-26</td>
<td>Survey questions related to HPV vaccine awareness, receipt of the vaccine, number of doses, perceived barriers, and relevant socio-demographic variables</td>
<td>-77.3% of women had not initiated the vaccine -reasoning of unvaccinated: 39.6% do not need the vaccine; 12.7% insufficient knowledge; 12.0% concerned about safety; 7.2% not recommended by physician; 6.7% not sexually active; 3.1% too old for vaccine - recall bias - survey did not assess sexual behavior therefore unable to associate vaccination with sexual behavior - unable to conclude causality</td>
<td>Increase in number of women 18-26 from 2008 survey, but still under-vaccinated. 2/3 on unvaccinated women were not interested in vaccination.</td>
<td></td>
</tr>
<tr>
<td>Navalpaka m, A./2016</td>
<td>IV</td>
<td>Cross sectional survey</td>
<td>1000 female Oakland University students 18 years old and above</td>
<td>- Knowledge of HPV Infection and Vaccination - Attitudes towards HPV Vaccination</td>
<td>- knowledge deficit evident by mean knowledge score of 53% - convenience sample - not representative of general population</td>
<td>Educational resources and activities, as well as awareness campaigns seem to be an inexpensive and effective way to</td>
<td></td>
</tr>
</tbody>
</table>

---

*HUMAN PAPILLOMAVIRUS VACCINATION*
<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Study Design</th>
<th>Methods</th>
<th>Study Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Niccolai, L. M.</td>
<td>2016</td>
<td>I Systematic Review</td>
<td>PubMed, Web of Science, MEDLINE search: - through July 2014 - search terms: HPV, Vaccine, intervention</td>
<td>- Reminder and Recall system - Physician focused intervention - School based programs - Social marketing - 79% thought HPV was a life-threatening disease improve disease knowledge, tolerance, and increase HPV vaccination rates</td>
</tr>
<tr>
<td>Obulaney, P. A.</td>
<td>2016</td>
<td>III Quasi-experimental design</td>
<td>- convenience sample of 41 mother/daughter dyads - pre and post test to determine knowledge of HPV - intervention: educational session – brochure, list of HPV preventative measures, video presentation including great detail about HPV infection and cervical cancer, and a Q&amp;A session</td>
<td>- great improvement in HPV knowledge after educational session – t=5.068, p&lt;0.0001 - 81% of mothers intend to vaccinate daughter after education information compared to 56% preintervention - small convenience sample - short study period - lack of translator - data collected from only one small clinic - All of the following had statistically significant increase in HPV vaccine compliance: - Reminder and Recall system - Physician focused intervention - School based programs - Social marketing</td>
</tr>
<tr>
<td>Oldach, B.</td>
<td>2012</td>
<td>IV Structured questionnaire via telephone contact</td>
<td>- data collected through a phone interview - Ask nurses at the health departments an estimate of HPV vaccine compliance rate and their perceived reasons for refusal among patients</td>
<td>- 66.7% of the health departments reports less than 50% of individuals ages 9-26 years of age had received the HPV vaccine - Reasons for refusal: lack of knowledge, concern of side effects, newness of the HPV vaccine, and parents believe their children are not sexually active - participants provide an estimate of the number of requests for HPV vaccine, HPV vaccine initiation and completion rates, provider recommendation patterns, HPV vaccine barriers, and patient cost information - less the 50% of individuals 9-26 years of age were vaccinated - improvement in HPV knowledge after education intervention - mothers were more likely to vaccinate their child after an education intervention than with no educational intervention</td>
</tr>
<tr>
<td>Patel, D. A.</td>
<td>2012</td>
<td>II RCT</td>
<td>- 256 participants from UHS gynecology clinic - intervention: educated with HPV and Vaccination fact sheet - reminder and fact sheet main 2 weeks after clinic visit</td>
<td>- 41% indicated an intent to receive vaccine – top reasons include not wanting to get cervical cancer and genital warts - 31.3% did not intend to undergo vaccination – reasons include concerned about safety, site effects, cost, not at risk - 5.5% received an initial does of HPV vaccine - may have received dose outside of specific clinic - college ages students - cost of vaccine - educational intervention was not statically relevant</td>
</tr>
<tr>
<td>Study</td>
<td>Study Design</td>
<td>Eligibility Criteria</td>
<td>Outcome Measures</td>
<td>Findings</td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>----------------------</td>
<td>------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Ratanasiripong, N. T./2012</td>
<td>Systematic Review</td>
<td>13 studies searched PubMed, MEDLINE, CINAHL, and Google Scholar</td>
<td>- 80.7% to 93.5% of participants thought that contracting HPV would be severe and having cervical cancer would be devastating. - 50% to 84.4% of participants did not think that they were at risk for HPV.</td>
<td>- Many studies were conducted when the vaccine first came out and attitudes have changed since that time. - Difference among studies in data collection methods.</td>
</tr>
<tr>
<td>Schmidt, S./2014</td>
<td>Cross-sectional, multipurpose health survey; multistage probability design</td>
<td>Women aged 18 – 26: 10513 – Vaccination initiation; 2817 interest in HPV vaccination; 1770 for nonvaccination</td>
<td>Outcomes: HPV vaccination uptake, Interest in HPV vaccine, and reasons for nonvaccination</td>
<td>- 76.7% had not initiated the HPV vaccine series. - Reason for not vaccinating 2010: 40.7% do not need vaccine; 11.8% don’t know enough about the vaccine; 12.3% worried about safety.</td>
</tr>
<tr>
<td>Small, S. L./2013</td>
<td>Systematic review</td>
<td>19 articles</td>
<td>Electronic database search: - Limitations: human, female, English, published between January 1, 2009 to June 1, 2011. - Direct measurement of uptake</td>
<td>- 6 influences: 1) cost and insurance coverage 2) provider recommendation 3) vaccination opportunity 4) HPV and HPV vaccine knowledge 5) vaccine safety concerns 6) HPV risk</td>
</tr>
<tr>
<td>Smulian, E. A./2016</td>
<td>Systematic review</td>
<td>34 studies addressing vaccination. - Adolescents and young adults</td>
<td>- Two authors searched PubMed, Web of Science, Wiley Online Library, Cumulative Index of Nursing and Allied Health Literature, and Google Scholar</td>
<td>- Many studies had limited generalizability in their results, as many have small sample sizes or were observational studies. - Single-method intervention strategies that frequently produce statistically significant increases in HPV vaccination coverage were reminder, recall, and patient education.</td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>Method</td>
<td>Participants</td>
<td>Interventions</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>--------</td>
<td>--------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Taylor, V. M./ 2014</td>
<td>IV</td>
<td>Survey</td>
<td>Sample size 86; Seattle metropolitan area: third largest Cambodian community in US; Cambodian mothers with daughters aged 9-17</td>
<td>Three survey interviewers who were bilingual Cambodian women; 9 months during 2012 to 2013; telephone interviews</td>
</tr>
<tr>
<td>Valdez, A./ 2015</td>
<td>II</td>
<td>RCT</td>
<td>708 Latino and Korean parents of unvaccinated 9-17 years of age</td>
<td>Education DVD was developed through focus groups and cognitive interviews; assess knowledge gains, decisional conflict, decision self-efficacy and informed decision making from view the DVD; Pre and Post intervention questionnaire</td>
</tr>
<tr>
<td>Wilson, A. R./ 2016</td>
<td>IV</td>
<td>Mailed survey</td>
<td>Survey mailed to 325 women ages 18-26 who attended the University of Utah Community Clinic</td>
<td>Survey mailed out to first 1000 individuals; survey mailed out to second 1000 individuals with return envelope and $5 for participation</td>
</tr>
<tr>
<td>Wong, C./ 2013</td>
<td>IV</td>
<td>Questionnaire</td>
<td>- Civilian, noninstitutionalized population in the United States: Families with girls aged 8-17; 2205 parents or parent proxies - Multistage area probability design</td>
<td>7 questions about the HPV vaccine</td>
</tr>
</tbody>
</table>
Appendix B

**Pre-intervention Survey**

1. On average, how many patients do you see in the clinic each week that are between the ages 18 and 26?
   a. 0-2
   b. 3-5
   c. 6-8
   d. 9 or more

2. How many of these patients, men and women aged 18 to 26, that you see each week, have initiated the Human Papilloma Virus (HPV) vaccine series?
   a. 0-2
   b. 3-5
   c. 6-8
   d. 9 or more

3. Approximately how many HPV series are initiated each week to patients between of ages of 18 to 26?
   a. 0-2
   b. 3-5
   c. 6-8
   d. 9 or more

4. What are the reasons patients refused the HPV vaccine? (Please Circle all that apply)
   Educational deficit  Cost  Side effects/Safety  Fear of Shots

5. What are the most common demographic categories of the patients that have received the HPV vaccine series in your practice? (Circle One for each category below)
   **Age Ranges in years:**  18 – 22 y/o  23 – 26 y/o
   **Gender:**  Female  Male
   **Race:**  White  African American  Hispanic  Asian  Other
Appendix C

Post-intervention Survey

1. On average, how many patients do you see in the clinic each week that are between the ages 18 and 26?
   a. 0-2
   b. 3-5
   c. 6-8
   d. 9 or more

2. How many of these patients, men and women aged 18 to 26, that you see each week, have *initiated* the Human Papilloma Virus (HPV) vaccine series?
   a. 0-2
   b. 3-5
   c. 6-8
   d. 9 or more

3. Approximately how many HPV series are initiated each week to patients between the ages of 18 and 26?
   a. 0-2
   b. 3-5
   c. 6-8
   d. 9 or more

4. What are the reasons patients refused the HPV vaccine? (Please Circle all that apply)
   Educational deficit   Cost   Side effects/Safety   Fear of Shots

5. Do you feel that the pamphlets were beneficial to your care related to HPV in young men and women aged 18 to 26?
   a. Yes
   b. No

6. What are the most common demographic categories of the patients that have received the HPV vaccine series in your practice? (Circle One for each category below)
   **Age Ranges in years:** 18 – 22 y/o   23 – 26 y/o
   **Gender:** Female   Male
   **Race:** White   African American   Hispanic   Asian   Other
KUMC HUMAN SUBJECTS COMMITTEE

REQUEST FOR
QUALITY IMPROVEMENT/QUALITY ASSURANCE DETERMINATION

*THIS FORM MUST BE TYPED*

<table>
<thead>
<tr>
<th>Project Leader:</th>
<th>Dr. Janet Pierce</th>
</tr>
</thead>
<tbody>
<tr>
<td>Department:</td>
<td>School of Nursing</td>
</tr>
<tr>
<td>Email:</td>
<td><a href="mailto:jpierce@kumc.edu">jpierce@kumc.edu</a></td>
</tr>
<tr>
<td>Phone:</td>
<td>913-588-1663</td>
</tr>
<tr>
<td>Alternate Contact Person (e.g., Project Coordinator):</td>
<td>Julie R. Jennings</td>
</tr>
<tr>
<td>Email:</td>
<td><a href="mailto:jjennings2@kumc.edu">jjennings2@kumc.edu</a></td>
</tr>
<tr>
<td>Phone:</td>
<td>620-290-2210</td>
</tr>
</tbody>
</table>

Project Title:
INCREASING HUMAN PAPILLOMAVIRUS VACCINATION IN YOUNG ADULTS

Project Number, Version and/or Date:
March 2017

1. Briefly state the purpose of the proposed project. *(Attach project plan if available.)*

   The aim of this quality improvement project will be to increase the number of HPV vaccines given to young adults (ages 18-26) through an educational pamphlet related to HPV and the HPV vaccines. The Project Director assumes that providing an educational pamphlet to young adults before they see their health care provider will increase the number of HPV vaccines administered at ComCare in Salina, Kansas.

2. Describe the research that has already demonstrated the effectiveness of your intervention. *(Cite research and/or attach documentation about the national program or standard you are implementing)*

   The goal of Health People 2020 is an 80% vaccination rate, which will require interventions to increase compliance with CDC recommendations related to the HPV vaccine.
Ratanasiripong (2012) determined there is a direct relationship between knowledge and the intent to vaccinate and the lack of knowledge related to HPV and the HPV vaccine can result in misconception and negative attitudes toward the vaccine. Laz, Rehman, and Berenson (2012) found that in 2010, 39% of women participants aged 18-26 did not get the HPV vaccine because they did not need the vaccine and 12.7% of women participants did not get the vaccine because they needed more information. Wilson, et al. (2016) also found that 28% of study participants did not receive the HPV vaccine because they needed more information. Knowledge deficits seemed to be a large issue related to not vaccinating for HPV throughout the literature. Smulian, Mitchell, and Stokley (2016) concluded that patient education showed a modest increase in the initiation of the HPV vaccine. Although there is not strong evidence indicating educational interventions will greatly impact the initiation of the HPV vaccine series, it is evident that there is a need for education related to HPV and the HPV vaccine.

3. **What types of data are needed for the project?**

This QI project will consist of qualitative data that are collected from a survey. The data will include information about providers’ recommendation and administration of the HPV vaccine, reasons seen for refusal of the vaccine, and patient demographics.

4. **Do you need access to identifiable patient records to complete the project?**

   - [X] NO
   - [ ] YES

   If yes, who holds the records? ______

   If yes, which patient identifiers or demographics are needed for the project? ______

5. **Which descriptions best fits your project?** *Check all that apply:*

   - [ ] Determine if a previously implemented clinical practice improved the quality of patient care
   - [ ] Evaluate or improve the local implementation of widely accepted clinical or educational standards that have been proven effective at other locations
   - [ ] Gather data on hospital or provider performance for clinical, practical or administrative uses
   - [ ] Conduct a needs assessment to guide future changes in local health care delivery or to support other improvements at KUMC
   - [ ] Perform an analysis to characterize our patient population/clients to improve quality of services
   - [X] Implement programs to enhance professional development for providers and trainees
   - [ ] Measure local efficiency, cost or satisfaction related to standard clinical practices
X Develop interventions or educational strategies that improve the utilization of recognized best practices
X Implement strategies to improve communication within our local healthcare environment
X Improve tools for patients that promote education, health literacy or treatment plan compliance

6. **Does your project involve any of the following aspects?** *Check all that apply:*

- [ ] Randomizing participants into two or more groups
- [ ] Student/residents/trainees are randomized
  - [ ] Patients are randomized
  - [ ] Healthcare providers are randomized
  - [ ] Units of the hospital are randomized
- [ ] Other *Specify: _____

- [x] Surveying a patient population
- [x] Developing clinical practice guidelines
- [ ] Developing new curriculum recommendations
- [ ] Developing or refining a new assessment tool
- [x] Implementing a novel approach to care that may improve patient outcomes

7. **Which institutions are involved in the project?**
   - KUMC only
   - Other institutions  List ComCare

8. **Which individuals or groups will receive the results of your project?**
   - Internal department personnel
   - Hospital representatives
   - [ ] University representatives
   - [x] Presentation/publication*
   - [ ] Other  Specify _____

9. **How will your results be used to implement local improvements?**
   If the pamphlets are determined to be beneficial, they will be implemented on a long-term basis at the clinic.

____________________________________   ____________________
Signature**        Date
Type/Print Name

*Any presentation or publication resulting from this project should explicitly state that it was undertaken as quality improvement.

**Ink signature or email from the project leader is required.
Appendix E

ComCare
520 S. Santa Fe Ave Suite 300
Salina, KS 67401

To whom it may concern,

I am a Family Nurse Practitioner student at The University of Kansas Medical Center. I am contacting you because you are a provider at ComCare in Salina, Kansas. I am recruiting participants to help in a quality improvement project to increase the administration of the Human Papillomavirus vaccine for young adults aged 18-26. I have developed an educational pamphlet using information from medical websites, as well the input of four medical professionals. The pamphlet will be placed in the waiting room of the clinic for patients to read as they wait to see their provider.

Participation in this quality improvement project involves completing a pre-and post-intervention survey that will take approximately 3 – 5 minutes. I am seeking your participation in this survey. No identifiable information will be collected about you or your patients and the survey is anonymous. There are no personal benefits or risks to participating in this survey. Participation is voluntary and you can stop taking the survey at any time. You will be notified when the surveys are available at the clinic.

If you have any questions, please contact Julie Jennings at (620) 290-2219 or jjennings2@kumc.edu. For questions about the rights of research participants, you may contact the KUMC Institutional Review Board (IRB) at (913) 588-1240 or humansubjects@kumc.edu

Sincerely,

Julie R. Jennings, RN, BSN
What is the HPV vaccine?

References

How do you pay for the vaccine?

Over time the vaccine may be available in more affordable options. If you do not have health insurance, talk with your provider to learn about more affordable options.

The vaccine is covered by all health insurance plans.

Most private insurance plans and insurance marketplaces include and pay for the HPV vaccine.

How do you get the vaccine?

Over time the vaccine may be available in more affordable options. If you do not have health insurance, talk with your provider to learn about more affordable options.

The vaccine is covered by all health insurance plans.

Most private insurance plans and insurance marketplaces include and pay for the HPV vaccine.

What are possible side effects of the vaccine?

Most common side effects include:

- Muscle or joint pain
- Nausea
- Headache or feeling tired
- Fever
- Pain, redness or swelling in the arm where the shot was given

How effective is the vaccine?

The HPV vaccine provides 95% protection against genital warts.

The vaccine is no more effective than 100% protection against genital warts.

There is no evidence that the HPV vaccine loses effectiveness over time.

The vaccine prevents 99% of cancers and nearly 100% of pre-cancer.

The vaccine provides over 90% protection against cancer.
What is Human Papillomavirus (HPV)?
- HPV is a group of more than 150 related viruses.
- HPV is transmitted through direct skin-to-skin contact, usually sexual contact.
- Nearly all sexually active men and women get HPV at some point in their lives. HPV is the most common sexually transmitted infection in the United States.
- HPV is the causative agent in genital warts and many cancers, with the most common being cervical cancer and oral cancer.

What is the treatment for HPV?
- There is no treatment for HPV. Associated lesions, such as genital warts and cancers, are treated in a variety of ways.

How do you protect yourself against HPV?
- Vaccination
- Abstinence
- Limited number of sexual partners
- Use of condoms

HPV Vaccine

Who can get the vaccine?
- The HPV vaccine can be given as early as age 9.
- Women can get the vaccine up to the age of 26.
- Heterosexual men can get the vaccine up to the age of 21.
- Homosexual men or immunocompromised men can get the vaccine up to the age of 26.

Who should not get the vaccine?
- Anyone who has had a severe allergic reaction to a dose of HPV vaccine should not get another one.
- Anyone who has a severe allergy to any component of HPV vaccine should not get the vaccine.
- HPV vaccine is not recommended for pregnant women.

How is the vaccine given?
- The vaccine is an intramuscular injection in the arm.
- If given before the age of 15, only two doses of the vaccine are given:
  - First dose
  - Second dose 6-12 months later
- If given at 15 years of age or older, three doses of the vaccine are given:
  - First dose
  - Second dose 1-2 months later
  - Third dose 6 months after first dose
Appendix G

June 29, 2017

To Whom It May Concern:

I am writing to confirm that University of Kansas School of Nursing DNP student Julie Jennings has been granted permission to complete her quality improvement project at our clinic. We look forward to hearing about her project findings at the conclusion of her time with us. Should you have further questions regarding our site please contact myself or Julie’s project co-chair Alison Hiatt, APRN by email at ahiatt@srhc.com or by telephone at 785-822-4739.

Sincerely,

Carl Roper
Director of Clinical Operations for Comcare
Salina Regional Health Center
785-823-7470

COMCARE Elm Street / 617 East Elm / Salina, Kansas 67401 / (785) 825-8221
COMCARE Santa Fe Street / 520 S. Santa Fe Ste. 300 / Salina, Kansas 67401 / (785) 823-7470
COMCARE Minneapolis / 311 North Mill / Minneapolis, Kansas 67467 / (785) 392-2144
STATCARE / 1001 S. Ohio / Salina, Kansas 67401 / (785) 827-6453
## Appendix H

On average, how many patients do you see in the clinic each week that are between the ages 18 and 26?

<table>
<thead>
<tr>
<th></th>
<th>Pre-survey</th>
<th>Post-survey</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. 0 – 2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>B. 3 – 5</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>C. 6 – 8</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>D. 9 or more</td>
<td>6</td>
<td>5</td>
</tr>
</tbody>
</table>

*Figure 1: Question 1*

How many of these patients, men and women age 18 to 26, that you see each week, have initiated the HPV vaccine series?

<table>
<thead>
<tr>
<th></th>
<th>Pre-survey</th>
<th>Post-survey</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. 0 – 2</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>B. 3 – 5</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>C. 6 – 8</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>D. 9 or more</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Figure 2: Question 2*

Approximately how many HPV series are initiated each week to patients between the ages of 18 and 26?

<table>
<thead>
<tr>
<th></th>
<th>Pre-survey</th>
<th>Post-survey</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. 0 – 2</td>
<td>9</td>
<td>6</td>
</tr>
<tr>
<td>B. 3 – 5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C. 6 – 8</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>D. 9 or more</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Figure 3: Question 3*
Figure 4: Reasons for vaccine refusal

Figure 5: Post-survey Question 5